natur
product
drug
discoveri
regain
interest
due
low
product
cost
structur
divers
multipl
use
activ
compound
treat
variou
diseas
attent
direct
toward
medicin
plant
plant
tradit
use
gener
treat
symptom
numer
diseas
establish
plant
harbour
microorgan
collect
known
endophyt
explor
asyet
untap
natur
product
endophyt
increas
chanc
find
novel
compound
concept
natur
product
target
microbi
pathogen
appli
isol
novel
antimycobacteri
compound
rapid
develop
drugresist
mycobacterium
tuberculosi
significantli
increas
need
new
treatment
pathogen
remain
import
continu
screen
novel
compound
natur
sourc
particularli
rare
encount
microorgan
endophyt
review
focus
bioprospect
polyketid
small
peptid
exhibit
antituberculosi
activ
although
current
treatment
tuberculosi
describ
establish
natur
product
structur
class
often
biosynthesis
microorgan
therefor
hypothesis
bioactiv
polyketid
peptid
origin
isol
plant
fact
produc
endophyt
interest
endophyt
natur
product
investig
need
novel
chemic
compound
treat
human
diseas
ever
increas
rapid
develop
drugresist
microb
discoveri
new
case
lifethreaten
infect
constant
recurr
diseas
push
advanc
field
drug
discoveri
strobel
et
al
demain
principl
three
pathway
discov
new
pharmacolog
signific
compound
ration
drug
design
drug
purpos
tailor
toward
specif
target
microbi
cell
mandal
et
al
combinatori
chemistri
involv
synthesi
combinatori
librari
compound
test
cellular
target
determin
potent
compound
gallop
et
al
natur
product
discoveri
isol
bioactiv
compound
biolog
sourc
strohl
late
pharmaceut
compani
shift
interest
toward
first
two
pathway
pathway
utilis
latest
advanc
threedimension
xray
crystallographi
drugdock
tool
computeraid
constitut
almost
new
drug
introduc
market
approxim
antiinfect
agent
natur
product
naturalproduct
deriv
newman
cragg
bioactiv
natur
product
abil
target
specif
protein
code
essenti
gene
kingston
understood
properti
fulli
utilis
human
genet
link
diseas
due
complex
human
proteinprotein
interact
et
al
attribut
wide
explor
treatment
infecti
diseas
compound
abl
specif
target
infect
agent
kingston
exampl
betalactam
antibiot
penicillin
cephalosporin
larg
use
broad
antibacteri
spectrum
outstand
safeti
profil
human
use
danzig
neuhaus
possibl
sourc
natur
product
plant
view
one
promis
plant
kingdom
provid
plethora
biolog
activ
compound
estim
exist
speci
higher
plant
investig
bisht
et
al
approxim
screen
biolog
activ
verpoort
medicin
plant
use
trace
ancient
agricultur
societi
indigen
popul
utilis
therapi
mani
diseas
davi
even
modern
era
approxim
world
popul
particularli
develop
countri
still
reli
herbal
medicin
primari
healthcar
guribfakim
histor
plant
heal
properti
discov
utilis
even
caus
diseas
fulli
identifi
surprisingli
trial
error
approach
utilis
gener
cultur
discov
plant
medicin
valu
unfortun
tradit
cultur
utilis
plant
medicin
purpos
preciou
knowledg
gener
kept
secret
tradit
healer
inform
kept
within
commun
inform
transfer
tradit
healer
modern
societi
larg
result
work
ethnobotanist
studi
planthuman
interrelationship
natur
social
context
alcorn
sinc
incept
field
ethnobotani
evolv
mere
collect
inform
regard
plant
utilis
particular
commun
complex
interdisciplinari
research
area
understand
biolog
socioeconom
impact
use
plant
develop
particular
cultur
ethnobotan
knowledg
provid
suffici
basi
investig
tradit
plant
medicin
properti
modern
scientist
revisit
tradit
use
plant
carri
bioprospect
involv
screen
natur
product
biolog
activ
strobel
daisi
ashforth
et
al
order
isol
identifi
chemic
entiti
respons
treat
diseas
sinc
discoveri
penicillin
fleme
mass
product
world
war
ii
modern
medicin
utilis
natur
product
singl
pharmaceut
entiti
concert
effort
made
isol
identifi
individu
bioactiv
compound
recent
past
isol
biolog
activ
natur
product
prefer
pathway
drug
discoveri
time
consum
resourc
ineffici
nonetheless
rate
bioassayguid
fraction
recent
significantli
improv
advanc
instrument
highperform
liquid
chromatographi
hplc
mass
spectrometri
ms
higher
magnet
fieldstrength
nuclear
magnet
reson
nmr
instrument
robot
technolog
salim
kinghorn
compound
limit
avail
organ
origin
detect
introduct
capillari
nmr
spectroscopi
martin
develop
autom
highthroughput
screen
techniqu
replac
bioassay
ratelimit
step
drug
discoveri
walter
namchuk
advanc
made
list
natur
product
therapeut
valu
ever
increas
abund
new
compound
continu
isol
ethnobotan
knowledg
led
isol
novel
bioactiv
compound
howev
plant
avail
view
limit
factor
commerci
success
natur
product
time
larg
quantiti
plant
requir
produc
suffici
amount
bioactiv
compound
clinic
use
case
compound
isol
endang
highli
endem
plant
rais
major
concern
regard
biodivers
conserv
plant
tissu
cultur
offer
solut
mcalpin
et
al
although
cost
product
method
high
one
advanc
address
issu
discoveri
microorgan
resid
insid
plant
tissu
may
produc
similar
bioactiv
compound
plant
host
commerci
point
view
rel
easier
scale
ferment
process
microb
enabl
largescal
product
biolog
activ
compound
meet
industri
demand
microorgan
present
opportun
discov
plethora
compound
offer
renew
sourc
natur
product
endophyt
refer
microorgan
mostli
fungi
bacteria
colonis
intercellular
intracellular
region
healthi
plant
tissu
particular
time
whose
presenc
unobtrus
asymptomat
schulz
boyl
stone
et
al
strobel
plant
speci
previous
studi
host
least
one
endophyt
microb
ryan
et
al
plant
grow
uniqu
environment
set
gener
host
novel
endophyt
microorgan
strobel
endophyt
form
symbiot
relationship
plant
host
believ
mani
case
microb
function
biolog
defenc
plant
foreign
phytopathogen
protect
mechan
endophyt
exert
directli
releas
metabolit
attack
antagonist
lyse
affect
cell
indirectli
either
induc
host
defenc
mechan
promot
growth
antibiot
hydrolyt
enzym
releas
endophyt
prevent
colonis
microbi
plant
pathogen
strobel
berg
hallmann
prevent
insect
azevedo
et
al
nematod
hallmann
et
al
infect
plant
case
endophyt
releas
metabolit
activ
host
defenc
mechan
pathogen
organ
process
known
induc
system
resist
kloepper
ryu
similarli
endophyt
also
promot
plant
growth
attempt
outcompet
cell
apoptosi
induc
infect
pathogen
berg
hallmann
plant
growth
promot
endophyt
may
exert
sever
mechan
product
phytohormon
tudzynski
synthesi
siderophor
osullivan
ogara
nitrogen
fixat
solubilis
miner
phosphoru
richardson
et
al
via
enzymat
activ
ethylen
suppress
deaminas
glick
et
al
plant
host
also
benefit
endophyt
natur
resist
soil
contamin
siciliano
et
al
abil
degrad
xenobiot
action
vector
introduc
degrad
trait
plant
substanti
assist
phytoremedi
ryan
et
al
endophyt
produc
similar
secondari
metabolit
host
bioactiv
compound
coproduc
plant
well
associ
endophyt
includ
anticanc
drug
camptothecin
puri
et
al
anticanc
drug
lead
compound
podophyllotoxin
puri
et
al
natur
insecticid
azadirachtin
kusari
et
al
sever
mechan
propos
simultan
product
biolog
compound
case
gibberellin
biosynthet
mechan
compound
evolv
independ
plant
microbi
counterpart
tudzynski
hand
horizont
gene
transfer
plant
host
endophyt
long
hypothesis
although
far
process
shown
occur
microbi
endophyt
taghavi
et
al
strongli
suggest
howev
interact
endophyt
respect
plant
host
contribut
coproduct
bioactiv
molecul
heinig
et
al
endophyt
recent
gener
signific
interest
microbi
chemistri
commun
due
immens
potenti
contribut
discoveri
new
bioactiv
compound
suggest
close
biolog
associ
endophyt
plant
host
result
product
greater
number
divers
biolog
molecul
compar
epiphyt
soilrel
microb
strobel
moreov
symbiot
natur
relationship
indic
endophyt
bioactiv
compound
like
possess
reduc
cell
toxic
chemic
kill
eukaryot
host
system
signific
medic
commun
potenti
drug
may
advers
affect
human
cell
one
success
stori
natur
product
endophyt
multibilliondollar
anticanc
drug
taxol
paclitaxel
compound
initi
isol
pacif
yew
tree
taxu
brevifolia
wani
et
al
tradit
medicin
plant
use
nativ
american
gunther
sinc
sever
plant
genu
taxu
report
produc
taxol
nonetheless
plant
slowgrow
gener
isol
geograph
distribut
investig
endophyt
plant
reveal
fungi
taxomyc
andreana
also
produc
exact
compound
stierl
et
al
biolog
product
compound
taxu
plant
characteris
fig
horizont
gene
transfer
long
propos
biosynthesi
taxol
endophyt
recent
show
endophyt
genom
contain
sequenc
signific
homolog
taxol
biosynthet
gene
taxu
spp
heinig
et
al
indic
taxol
biosynthesi
endophyt
might
develop
independ
plant
host
nevertheless
exampl
support
rational
tradit
medicin
plant
use
start
point
investig
endophyt
product
biolog
activ
compound
mention
earlier
approxim
three
quarter
antiinfect
natur
product
naturalproduct
deriv
structur
howev
rather
use
combinatori
chemistri
synthesis
deriv
biosynthesi
natur
product
elucid
genet
level
synthesi
natur
product
regul
singl
gene
cluster
numer
research
group
attempt
isol
cluster
utilis
genet
engin
biolog
synthesis
nativ
compound
well
deriv
two
studi
largest
class
secondari
metabolit
polyketid
nonribosom
peptid
hoffmeist
keller
peptid
antibiot
constitut
import
antiinfect
drug
market
notabl
penicillin
cephalosporin
paradkar
et
al
oligopeptid
synthesis
larg
multimodular
enzym
complex
call
nonribosom
peptid
synthetas
nrpss
use
proteinogen
nonproteinogen
amino
acid
build
block
nrpss
consist
seri
modul
consist
catalyt
unit
essenti
amino
acid
recognit
adenyl
domain
activ
peptidyl
carrier
protein
bond
format
grow
peptid
chain
condens
domain
fischbach
walsh
variabl
arrang
modul
possibl
inclus
numer
tailor
reaction
result
vast
array
nonribosom
peptid
scaffold
natur
high
versatil
modul
domain
term
catalyt
potenti
interact
within
multifunct
protein
templat
led
classif
nrp
system
linear
type
iter
type
b
nonlinear
type
c
mootz
et
al
linear
type
nrpss
multipl
modul
arrang
sequenti
fashion
modul
incorpor
one
monom
grow
chain
product
cycl
contrast
iter
type
b
npr
system
modul
domain
use
multipl
time
assembl
singl
product
thu
creat
multimer
peptid
consist
repeat
smaller
sequenc
third
type
nonlinear
type
c
nrpss
sophist
system
consist
domain
modul
organis
nonconvent
manner
deviat
tradit
capcp
arrang
often
follow
unusu
intern
cyclis
branchpoint
synthes
result
nonlinear
peptid
product
exampl
type
nrp
product
daptomycin
cyclic
lipopeptid
repres
first
new
class
antibiot
introduc
year
approv
food
drug
administr
fda
raja
et
al
natur
produc
actinomycet
streptomyc
roseosporu
daptomycin
consist
cyclic
core
aminoacid
six
nonproteinogen
ntermin
decanoyl
lipid
fig
miao
et
al
valinomycin
potent
antibiot
sever
acut
respiratori
syndrom
coronaviru
provid
good
model
type
b
iter
nrp
system
produc
sever
streptomyc
isol
biosynthet
gene
cluster
isol
streptomyc
tsusimaensi
fig
cheng
third
type
nonlinear
type
c
nrpss
respons
biosynthesi
potent
antituberculosi
compound
capreomycin
isol
saccharothrix
mutabili
subsp
capreolu
analysi
capreomycin
biosynthet
gene
cluster
reveal
compound
assembl
typic
linear
iter
nrp
mechan
fig
felnagl
et
al
similar
small
peptid
polyketid
also
constitut
larg
proport
industri
antibiot
among
promin
exampl
polyen
macrolid
antibiot
amphotericin
b
nystatin
gil
well
tetracyclin
paradkar
et
al
polyketid
natur
product
synthesis
polyketid
synthas
pk
also
larg
multimodular
enzym
complex
function
similarli
fatti
acid
synthas
fa
fischbach
walsh
multipl
arrow
indic
sever
yet
undefin
step
system
acyltransferas
act
gatekeep
substrat
specif
select
activ
monom
intermedi
acyl
chain
acyl
carrier
protein
acp
whose
phosphopantethein
arm
coval
attach
grow
intermedi
acyl
chain
ketosynthas
ks
catalys
c
c
bond
format
via
claisen
condens
elong
polyketid
chain
fischbach
walsh
termin
achiev
action
thioesteras
te
domain
sever
type
pk
system
type
pkss
multifunct
enzym
linearli
arrang
modul
consist
set
nonit
act
domain
respons
catalysi
one
cycl
chain
elong
bisang
et
al
erythromycin
broad
spectrum
macrolid
antibiot
one
wellstudi
compound
type
rawl
first
discov
saccharopolyspora
erythraea
compound
consist
macrolacton
ring
two
glucos
deriv
deoxysugar
moieti
desosamin
cladinos
construct
precursor
b
control
larg
modular
protein
known
synthas
deb
fig
type
ii
pkss
consist
sever
monofunct
enzym
act
iter
result
product
polyphenol
aromat
polyketid
hertweck
et
al
exampl
type
antitumour
antibiot
doxorubicin
produc
actinomycet
streptomyc
peucetiu
fig
grimm
et
al
type
iii
pkss
also
known
chalcon
synthaselik
pkss
homodimer
enzym
consist
multipl
acpindepend
modul
essenti
iter
condens
enzym
biosynthesi
antibiot
plant
pathogen
endophyt
pseudomona
fluorescen
known
involv
type
iii
polyketid
synthas
fig
gita
bangera
thomashow
plantassoci
microorgan
found
produc
novel
bioactiv
metabolit
widerang
medicin
applic
antibiot
immunosuppress
antiparasit
anticanc
agent
stierl
et
al
therefor
hypothesis
endophyt
could
use
sourc
lead
compound
drug
discoveri
highlight
earlier
natur
product
abil
target
microbi
pathogen
interest
scientif
medic
commun
sinc
infecti
diseas
lead
caus
human
mortal
global
one
diseas
increasingli
affect
larg
human
popul
tuberculosi
number
natur
antimycobacteri
discuss
later
review
also
identifi
pk
nrp
product
especi
produc
bacteria
fungi
tuberculosi
tb
potenti
deadli
infecti
diseas
caus
mycobacterium
sp
mainli
mycobacterium
tuberculosi
often
infect
lung
also
attack
central
nervou
system
lymphat
system
well
skelet
tissu
common
symptom
tb
includ
chronic
cough
bloodting
sputum
fever
night
sweat
weight
loss
tb
transmit
air
infect
individu
cough
sneez
spit
spread
bacteria
throat
lung
pestka
acquisit
aminoglycosideinactiv
enzym
shaw
et
al
mutat
alter
target
structur
gene
rr
alangaden
et
al
ribosom
protein
finken
et
al
dcycloserin
cyclic
analogu
dalanin
inhibit
cell
wall
biosynthesi
halouska
et
al
overexpress
target
gene
alra
et
al
ethambutol
inhibit
cell
wall
biosynthesi
wolucka
et
al
lee
et
al
mutat
target
operon
embcab
particularli
gene
embb
ramaswami
et
al
ethionamid
prothionamid
structur
analogu
isoniazid
inhibit
cell
wall
particularli
mycol
acid
biosynthesi
banerje
et
al
baulard
et
al
mutat
target
gene
inha
banerje
et
al
overexpress
ethr
repressor
ethionamid
activ
engohangndong
et
al
fluoroquinolon
ciprofloxacin
gatifloxacin
levofloxacin
moxifloxacin
ofloxacin
sparfloxacin
inhibit
dna
replic
drlica
zhao
mutat
target
gene
gyra
drlica
zhao
alangaden
et
al
gryb
aubri
et
al
isoniazid
inhibit
fatti
acid
biosynthesi
banerje
et
al
takayama
et
al
rozwarski
et
al
mutat
katg
gene
prevent
drug
activ
zhang
et
al
mutat
target
structur
gene
inha
rous
et
al
bergval
et
al
isoxyl
inhibit
mycol
acid
oleic
acid
tuberculostrear
acid
shortchain
fatti
acid
biosynthesi
phetsuksiri
et
al
mutat
target
gene
etaa
possibl
crossresist
thiocarbonylcontain
antibiot
debarb
et
al
macrolid
erythromycin
clarithromycin
roxithromycin
inhibit
protein
synthesi
particularli
translat
initi
taubman
et
al
point
mutat
target
rrna
gene
meier
et
al
nakajima
increas
express
ermmt
gene
result
substanti
loss
drug
bind
andini
nash
oxazolidinon
linezolid
eperezolid
inhibit
protein
synthesi
particularli
translat
initi
shinabarg
et
al
alter
efflux
pump
drug
transport
mechan
richter
et
al
paminosalicyl
acid
inhibit
folat
rengarajan
et
al
thymin
nucleotid
mathi
et
al
mutat
target
gene
thya
though
major
caus
yet
identifi
mathi
et
al
phenothiazin
thioridazin
chlorpromazin
trifluoperazin
inhibit
cell
wall
biosynthesi
lipid
metabol
reddi
et
al
oxid
phosphoryl
yano
et
al
yet
identifi
amar
pyrazinamid
synthet
analogu
nicotinamid
mechan
fulli
understood
though
thought
inhibit
vital
enzym
activ
disrupt
membran
transport
heifet
lindholmlevi
zhang
et
al
zhang
mitchison
mutat
gene
pnca
prevent
drug
activ
scorpio
et
al
rifamycin
rifampin
rifabutin
rifalazil
rifapentin
inhibit
protein
synthesi
particularli
transcript
initi
kunin
induct
program
cell
death
engelbergkulka
et
al
mutat
target
structur
gene
rpob
telenti
et
al
riminophenazin
clofazimin
disrupt
potassium
transport
cholo
et
al
electron
transport
involv
cellular
respir
boshoff
et
al
yet
identifi
inhibit
protein
synthesi
particularli
posttranscript
modif
translat
initi
thoma
et
al
liou
tanaka
wank
et
al
singl
doubl
mutat
target
ribosom
subunit
gene
felnagl
et
al
yamada
et
al
taniguchi
et
al
onethird
world
current
popul
infect
tuberculosi
koul
et
al
approxim
million
report
case
activ
tb
million
new
relaps
case
diseas
caus
approxim
million
death
world
health
organ
though
tb
incid
common
develop
underdevelop
countri
world
health
organ
rise
frequenc
popul
migrat
result
increas
occurr
develop
countri
case
tb
curabl
provid
drug
regim
follow
dilig
frieden
et
al
antitb
drug
regim
consid
success
mycobacteria
kill
prevent
patient
relaps
cessat
treatment
avoid
develop
drug
resist
mycobacteria
natur
occur
drugresist
mycobacteria
stage
infect
current
imposs
treat
diseas
singl
drug
grosset
drug
commonli
use
treat
tb
list
tabl
typic
drug
regim
compris
combin
bactericid
bacteriostat
drug
sinc
standard
firstlin
therapi
tuberculosi
involv
two
month
treatment
combin
rifampicin
isoniazid
ethambutol
pyrazinamid
follow
treatment
combin
rifampicin
isoniazid
addit
four
month
grosset
unfortun
stringent
drug
therapi
access
suffer
particularli
high
burden
countri
asia
africa
incomplet
treatment
diseas
caus
develop
drugresist
tb
tuberculosi
intrins
drug
resist
mechan
render
antimicrobi
ineffect
uniqu
lipidrich
cell
envelop
structur
low
permeabl
clinic
antibiot
jarlier
nikaido
equip
drug
efflux
pump
louw
et
al
provid
drug
abl
penetr
cell
wall
mycobacteria
anoth
complementari
system
coordin
resist
antibiot
inhibit
cytoplasm
target
hand
tuberculosi
known
possess
genom
plastic
domenech
et
al
case
drug
resist
tuberculosi
develop
via
mutat
andri
et
al
koul
et
al
target
atp
synthas
inhibit
proton
pump
activ
huitric
et
al
iii
fdaapprov
acceler
programm
cohen
tb
allianc
nitroimidazol
ngml
stover
et
al
prevent
cell
wall
mycol
acid
biosynthesi
maroz
et
al
manjunatha
et
al
manjunatha
et
al
ii
jone
opc
delamanid
otsuka
nitroimidazol
ngml
matsumoto
et
al
prevent
cell
wall
mycol
acid
biosynthesi
gler
et
al
iii
jone
sequella
ethylenediamin
ngml
sacksted
et
al
inhibit
mycol
acid
transport
cell
wall
boshoff
et
al
tahlan
et
al
ii
sacksted
et
al
sutezolid
pfizer
oxazolidinon
ngml
barbachyn
et
al
target
rrna
inhibit
bacteri
protein
synthesi
patel
et
al
ii
jone
astrazeneca
oxazolidinon
undisclos
data
undisclos
dataii
jone
target
gene
rpob
rifampicin
rr
kanamycin
gyra
fluoroquinon
multidrug
resist
occur
via
accumul
independ
mutat
one
gene
rattan
et
al
one
major
issu
antimycobacteri
research
absenc
new
drug
novel
mechan
action
resist
observ
current
therapeut
cuttingedg
technolog
advanc
screen
process
result
sever
drug
candid
novel
activ
current
test
later
stage
clinic
trial
tabl
new
drug
candid
semisynthet
receiv
fda
approv
specif
patient
mdrtb
acceler
approv
programm
base
decis
phase
ii
trial
cohen
diacon
et
al
diacon
et
al
commercialis
name
bedaquilin
first
antitb
therapi
novel
mechan
action
year
osborn
natur
product
play
crucial
role
treatment
tb
global
effort
decreas
incid
tb
combin
rapid
develop
resist
strain
increas
interest
natur
product
sourc
novel
antitubercular
compound
develop
vitro
whole
organ
report
bioassay
changsen
et
al
purifi
target
biochem
bioassay
schaeffer
et
al
scherman
et
al
vivo
bioassay
lenaert
et
al
acceler
assess
process
drug
candid
thu
consider
increas
discoveri
rate
new
compound
novel
antitubercular
agent
identifi
characteris
biolog
sourc
copp
pearc
novel
entiti
identifi
salomon
schmidt
furthermor
novel
compound
isol
microbi
sourc
list
tabl
polyketid
polyketidederiv
small
peptid
highlight
signific
class
natur
product
natur
product
drug
discoveri
work
basi
biolog
divers
key
chemic
divers
singh
pelaez
one
prerequisit
discoveri
novel
bioactiv
compound
choos
suitabl
sourc
materi
significantli
increas
chanc
hit
target
plant
long
view
common
sourc
remedi
either
form
tradit
prepar
pure
activ
principl
form
strong
basi
utilis
local
plant
tradit
use
medicin
investig
activ
chemic
constitu
fact
norman
r
farnsworth
one
pioneer
field
pharmacognosi
studi
tradit
medicin
highlight
compound
isol
plant
utilis
singl
entiti
medicin
agent
farnsworth
et
al
importantli
compound
obtain
result
examin
plant
base
ethnomed
use
utilis
manner
similar
tradit
use
emphasis
rational
investig
tradit
medicin
plant
chemic
discoveri
addit
increas
chemic
divers
base
premis
plant
host
number
endophyt
microorgan
benefici
explor
microb
discov
novel
compound
exampl
provid
group
microbiologist
thailand
investig
fungal
endophyt
local
medicin
plant
bioactiv
wiyakrutta
et
al
shown
morpholog
distinct
endophyt
fungi
extract
isol
found
inhibit
growth
tuberculosi
h
ra
mic
gml
inhibit
plasmodium
falciparum
ic
gml
show
antivir
activ
herp
simplex
viru
type
ic
gml
exhibit
antiprolif
activ
human
oral
epidermoid
carcinoma
cell
line
ec
gml
extract
anticanc
activ
breast
cancer
cell
ec
gml
exampl
highlight
mutual
relationship
biolog
divers
drug
discoveri
endophyt
potenti
sourc
novel
bioactiv
compound
nonetheless
fine
screen
purif
identif
method
requir
target
activ
compound
sinc
microorgan
may
contain
larg
pool
compound
bioactiv
exampl
cultur
endophyt
tradit
chines
medicin
plant
miller
et
al
bacteri
fungal
endophyt
eight
plant
tradit
use
anticanc
therapi
screen
genet
presenc
pk
nrp
system
assay
investig
antibacteri
antifung
cytotox
trait
also
perform
use
crude
extract
endophyt
eight
plant
host
bacteri
endophyt
belong
genera
well
fungal
endophyt
genera
moreov
bacteri
endophyt
fungal
endophyt
possess
pk
machineri
bacteri
endophyt
fungal
endophty
least
nrp
gene
cluster
endophyt
equip
either
pk
andor
nrp
system
exhibit
antiprolif
effect
least
one
bioassay
exampl
shown
tradit
medicin
plant
harbour
endophyt
produc
bioactiv
natur
product
dalimartha
also
strong
correl
pksnrp
gene
bioactiv
thu
combin
geneticand
bioactivitybas
derepl
step
streamlin
method
bioactiv
natur
product
discoveri
develop
indonesia
one
world
largest
floral
divers
larg
due
complex
geolog
histori
exist
larg
number
island
endem
speci
tropic
climat
support
growth
divers
rang
plant
indonesia
contain
two
world
biodivers
hotspot
sundaland
wallacea
region
differ
plant
speci
endem
myer
et
al
plant
speci
approxim
believ
possess
medicin
characterist
schumach
mani
investig
indonesian
tradit
herbal
medicin
collect
refer
jamu
achiev
worldwid
reput
use
treat
variou
diseas
approxim
threequart
countri
popul
consum
variou
type
jamu
regular
basi
healthcar
steffan
et
al
tradit
medicin
develop
jamu
start
random
experi
discov
benefici
properti
plant
stevensen
tradit
healer
possess
advanc
knowledg
plant
occupi
privileg
posit
societi
schumach
knowledg
mainli
pass
verbal
gener
gener
limyati
juniar
ethnobotan
drug
discoveri
effort
result
discoveri
polyphenol
two
frequent
use
tradit
indonesian
medicin
plant
steffan
et
al
guazuma
ulmifolia
lam
local
name
daun
jati
belanda
tradit
use
treat
liver
diseas
sauropu
androgynu
merr
local
name
daun
katuk
reduc
fever
research
believ
benefici
effect
plant
associ
antioxid
activ
polyphenol
subsequ
phytochem
investig
isol
kaempferol
androgynu
luteolin
g
ulmifolia
antioxid
properti
compound
confirm
vitro
test
use
rat
hepatoma
cell
cultur
around
world
number
plant
utilis
indonesian
tradit
herbalist
treat
commonli
know
tb
tabl
worth
note
knowledg
diseas
limit
plant
use
tradit
therapi
know
tb
base
symptom
patient
exhibit
cough
bloodting
sputum
short
breath
small
proport
indonesian
medicin
plant
extens
studi
contain
specif
antitubercular
compound
plant
remain
understudi
may
host
mani
endophyt
antibiot
compound
persist
battl
pathogen
drug
thu
constant
urgenc
discov
novel
antibiot
microorgan
particularli
rapidli
develop
drug
resist
strain
tuberculosi
critic
first
step
discov
novel
bioactiv
compound
pinpoint
suitabl
sourc
materi
accord
professor
gari
strobel
one
pioneer
endophyt
studi
three
import
criteria
bioprospect
signific
biodivers
histori
longterm
human
habit
presenc
nativ
healer
knowledg
local
medicin
plant
gordon
home
largest
tropic
rainforest
world
indonesia
offer
incred
rang
biodivers
never
investig
biolog
divers
often
translat
molecular
divers
increas
possibl
isol
new
chemic
entiti
utilis
tradit
knowledg
studi
plant
use
treat
symptom
respiratori
diseas
may
assist
narrow
plant
target
investig
product
novel
antimycobacteri
compound
furthermor
base
premis
mani
plant
bioactiv
compound
actual
produc
microbi
symbiont
explor
endophyt
medicin
plant
assist
isol
produc
activ
compon
ultim
aim
bioprospect
novel
compound
isol
compound
safe
efficaci
human
use
effici
screen
mechan
crucial
target
potenti
bioactiv
compound
prior
knowledg
biosynthesi
polyketid
small
nonribosom
peptid
greatli
assist
derepl
plethora
compound
produc
singl
microorgan
structur
elucid
isol
chemic
characteris
biosynthet
pathway
provid
basi
novel
compound
investig
clinic
trial
commerci
purpos
potenti
antimycobacteri
drug
discoveri
endophyt
tradit
medicin
plant
immens
